These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 31292201)

  • 1.
    Hillman JC; Pugacheva EM; Barger CJ; Sribenja S; Rosario S; Albahrani M; Truskinovsky AM; Stablewski A; Liu S; Loukinov DI; Zentner GE; Lobanenkov VV; Karpf AR; Higgins MJ
    Mol Cancer Res; 2019 Oct; 17(10):2051-2062. PubMed ID: 31292201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
    Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
    Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
    [No Abstract]   [Full Text] [Related]  

  • 3. Increased expression of neurotensin in high grade serous ovarian carcinoma with evidence of serous tubal intraepithelial carcinoma.
    Norris EJ; Zhang Q; Jones WD; DeStephanis D; Sutker AP; Livasy CA; Ganapathi RN; Tait DL; Ganapathi MK
    J Pathol; 2019 Jul; 248(3):352-362. PubMed ID: 30883751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypomethylation of the CTCFL/BORIS promoter and aberrant expression during endometrial cancer progression suggests a role as an Epi-driver gene.
    Hoivik EA; Kusonmano K; Halle MK; Berg A; Wik E; Werner HM; Petersen K; Oyan AM; Kalland KH; Krakstad C; Trovik J; Widschwendter M; Salvesen HB
    Oncotarget; 2014 Feb; 5(4):1052-61. PubMed ID: 24658009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A genetically engineered ovarian cancer mouse model based on fallopian tube transformation mimics human high-grade serous carcinoma development.
    Sherman-Baust CA; Kuhn E; Valle BL; Shih IeM; Kurman RJ; Wang TL; Amano T; Ko MS; Miyoshi I; Araki Y; Lehrmann E; Zhang Y; Becker KG; Morin PJ
    J Pathol; 2014 Jul; 233(3):228-37. PubMed ID: 24652535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coordinated cancer germline antigen promoter and global DNA hypomethylation in ovarian cancer: association with the BORIS/CTCF expression ratio and advanced stage.
    Woloszynska-Read A; Zhang W; Yu J; Link PA; Mhawech-Fauceglia P; Collamat G; Akers SN; Ostler KR; Godley LA; Odunsi K; Karpf AR
    Clin Cancer Res; 2011 Apr; 17(8):2170-80. PubMed ID: 21296871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biological and prognostic value of ETV5 in high-grade serous ovarian cancer.
    Zhang L; Fu R; Liu P; Wang L; Liang W; Zou H; Jia W; Tao L
    J Ovarian Res; 2021 Nov; 14(1):149. PubMed ID: 34736492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. YAP induces high-grade serous carcinoma in fallopian tube secretory epithelial cells.
    Hua G; Lv X; He C; Remmenga SW; Rodabough KJ; Dong J; Yang L; Lele SM; Yang P; Zhou J; Karst A; Drapkin RI; Davis JS; Wang C
    Oncogene; 2016 Apr; 35(17):2247-65. PubMed ID: 26364602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MAGEA1 inhibits the expression of BORIS via increased promoter methylation.
    Zhao J; Wang Y; Liang Q; Xu Y; Sang J
    J Cell Sci; 2019 Jan; 132(1):. PubMed ID: 30498011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MiR-125a regulates ovarian cancer proliferation and invasion by repressing GALNT14 expression.
    Yang J; Li G; Zhang K
    Biomed Pharmacother; 2016 May; 80():381-387. PubMed ID: 27133078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA methylation-dependent regulation of BORIS/CTCFL expression in ovarian cancer.
    Woloszynska-Read A; James SR; Link PA; Yu J; Odunsi K; Karpf AR
    Cancer Immun; 2007 Dec; 7():21. PubMed ID: 18095639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GALNT14 mediates tumor invasion and migration in breast cancer cell MCF-7.
    Huanna T; Tao Z; Xiangfei W; Longfei A; Yuanyuan X; Jianhua W; Cuifang Z; Manjing J; Wenjing C; Shaochuan Q; Feifei X; Naikang L; Jinchao Z; Chen W
    Mol Carcinog; 2015 Oct; 54(10):1159-71. PubMed ID: 24962947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Altered expression of different GalNAc‑transferases is associated with disease progression and poor prognosis in women with high-grade serous ovarian cancer.
    Sheta R; Bachvarova M; Plante M; Gregoire J; Renaud MC; Sebastianelli A; Popa I; Bachvarov D
    Int J Oncol; 2017 Dec; 51(6):1887-1897. PubMed ID: 29039611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BORIS/CTCFL expression is insufficient for cancer-germline antigen gene expression and DNA hypomethylation in ovarian cell lines.
    Woloszynska-Read A; James SR; Song C; Jin B; Odunsi K; Karpf AR
    Cancer Immun; 2010 Jul; 10():6. PubMed ID: 20649179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting IDH1 as a Prosenescent Therapy in High-grade Serous Ovarian Cancer.
    Dahl ES; Buj R; Leon KE; Newell JM; Imamura Y; Bitler BG; Snyder NW; Aird KM
    Mol Cancer Res; 2019 Aug; 17(8):1710-1720. PubMed ID: 31110157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Defining the molecular evolution of extrauterine high grade serous carcinoma.
    Beirne JP; McArt DG; Roddy A; McDermott C; Ferris J; Buckley NE; Coulter P; McCabe N; Eddie SL; Dunne PD; O'Reilly P; Gilmore A; Feeney L; Ewing DL; Drapkin RI; Salto-Tellez M; Kennedy RD; Harley IJG; McCluggage WG; Mullan PB
    Gynecol Oncol; 2019 Nov; 155(2):305-317. PubMed ID: 31493898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of MicroRNA-200 pathway in ovarian cancer and serous intraepithelial carcinoma of fallopian tube.
    Yang J; Zhou Y; Ng SK; Huang KC; Ni X; Choi PW; Hasselblatt K; Muto MG; Welch WR; Berkowitz RS; Ng SW
    BMC Cancer; 2017 Jun; 17(1):422. PubMed ID: 28623900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early Loss of Histone H2B Monoubiquitylation Alters Chromatin Accessibility and Activates Key Immune Pathways That Facilitate Progression of Ovarian Cancer.
    Hooda J; Novak M; Salomon MP; Matsuba C; Ramos RI; MacDuffie E; Song M; Hirsch MS; Lester J; Parkash V; Karlan BY; Oren M; Hoon DS; Drapkin R
    Cancer Res; 2019 Feb; 79(4):760-772. PubMed ID: 30563893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BORIS/CTCFL mRNA isoform expression and epigenetic regulation in epithelial ovarian cancer.
    Link PA; Zhang W; Odunsi K; Karpf AR
    Cancer Immun; 2013; 13():6. PubMed ID: 23390377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovering a binary CTCF code with a little help from BORIS.
    Lobanenkov VV; Zentner GE
    Nucleus; 2018 Jan; 9(1):33-41. PubMed ID: 29077515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.